These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31775034)

  • 21. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.
    Morelli E; Leone E; Cantafio ME; Di Martino MT; Amodio N; Biamonte L; Gullà A; Foresta U; Pitari MR; Botta C; Rossi M; Neri A; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
    Leukemia; 2015 Nov; 29(11):2173-83. PubMed ID: 25987254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A neomorphic mutation in the interferon activation domain of IRF4 causes a dominant primary immunodeficiency.
    Thouenon R; Chentout L; Moreno-Corona N; Poggi L; Lombardi EP; Hoareau B; Schmitt Y; Lagresle-Peyrou C; Bustamante J; André I; Cavazzana M; Durandy A; Casanova JL; Galicier L; Fadlallah J; Fischer A; Kracker S
    J Exp Med; 2023 Jun; 220(6):. PubMed ID: 36917008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
    Lopez-Girona A; Heintel D; Zhang LH; Mendy D; Gaidarova S; Brady H; Bartlett JB; Schafer PH; Schreder M; Bolomsky A; Hilgarth B; Zojer N; Gisslinger H; Ludwig H; Daniel T; Jäger U; Chopra R
    Br J Haematol; 2011 Aug; 154(3):325-36. PubMed ID: 21707574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker.
    Ryu D; Kim HJ; Joung JG; Lee HO; Bae JS; Kim SJ; Kim H; Park WY; Kim K
    Oncotarget; 2016 Jul; 7(30):47127-47133. PubMed ID: 27223072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption.
    Mondala PK; Vora AA; Zhou T; Lazzari E; Ladel L; Luo X; Kim Y; Costello C; MacLeod AR; Jamieson CHM; Crews LA
    Cell Stem Cell; 2021 Apr; 28(4):623-636.e9. PubMed ID: 33476575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination.
    Klein U; Casola S; Cattoretti G; Shen Q; Lia M; Mo T; Ludwig T; Rajewsky K; Dalla-Favera R
    Nat Immunol; 2006 Jul; 7(7):773-82. PubMed ID: 16767092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells.
    Teng Y; Takahashi Y; Yamada M; Kurosu T; Koyama T; Miura O; Miki T
    Eur J Cell Biol; 2007 Oct; 86(10):581-9. PubMed ID: 17651861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells.
    Weinhold N; Meissner T; Johnson DC; Seckinger A; Moreaux J; Försti A; Chen B; Nickel J; Chubb D; Rawstron AC; Doughty C; Dahir NB; Begum DB; Young K; Walker BA; Hoffmann P; Nöthen MM; Davies FE; Klein B; Goldschmidt H; Morgan GJ; Houlston RS; Hose D; Hemminki K
    Haematologica; 2015 Mar; 100(3):e110-3. PubMed ID: 25480495
    [No Abstract]   [Full Text] [Related]  

  • 29. IRF4 Is a Critical Gene in Retinoic Acid-Mediated Plasma Cell Formation and Is Deregulated in Common Variable Immunodeficiency-Derived B Cells.
    Indrevær RL; Moskaug JØ; Paur I; Bøhn SK; Jørgensen SF; Blomhoff R; Aukrust P; Fevang B; Blomhoff HK
    J Immunol; 2015 Sep; 195(6):2601-11. PubMed ID: 26276871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
    Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells.
    Vora AA; Mondala PK; Costello C; MacLeod AR; Crews LA
    STAR Protoc; 2021 Jun; 2(2):100565. PubMed ID: 34136833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon regulatory factor 4 regulates thymocyte differentiation by repressing Runx3 expression.
    Cao Y; Li H; Sun Y; Chen X; Liu H; Gao X; Liu X
    Eur J Immunol; 2010 Nov; 40(11):3198-209. PubMed ID: 21061442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.
    Butrym A; Łacina P; Rybka J; Chaszczewska-Markowska M; Mazur G; Bogunia-Kubik K
    Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):151-156. PubMed ID: 28083618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IRF4 controls the positioning of mature B cells in the lymphoid microenvironments by regulating NOTCH2 expression and activity.
    Simonetti G; Carette A; Silva K; Wang H; De Silva NS; Heise N; Siebel CW; Shlomchik MJ; Klein U
    J Exp Med; 2013 Dec; 210(13):2887-902. PubMed ID: 24323359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IRF4 is a novel mediator for neuronal survival in ischaemic stroke.
    Guo S; Li ZZ; Jiang DS; Lu YY; Liu Y; Gao L; Zhang SM; Lei H; Zhu LH; Zhang XD; Liu DP; Li H
    Cell Death Differ; 2014 Jun; 21(6):888-903. PubMed ID: 24510125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Essential role of interferon regulatory factor 4 (IRF4) in immune cell development.
    Nam S; Lim JS
    Arch Pharm Res; 2016 Nov; 39(11):1548-1555. PubMed ID: 27826752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma.
    Conery AR; Centore RC; Neiss A; Keller PJ; Joshi S; Spillane KL; Sandy P; Hatton C; Pardo E; Zawadzke L; Bommi-Reddy A; Gascoigne KE; Bryant BM; Mertz JA; Sims RJ
    Elife; 2016 Jan; 5():. PubMed ID: 26731516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown.
    Lin FR; Kuo HK; Ying HY; Yang FH; Lin KI
    Cancer Res; 2007 Dec; 67(24):11914-23. PubMed ID: 18089822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells.
    Gao Y; Wang L; Lei Z; Li J; Forrest JC; Liang X
    J Gen Virol; 2019 May; 100(5):851-862. PubMed ID: 30907723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.